

FORM PTO-1449/A and B (modified PTO/SB/08)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/735,592

ATTY. DOCKET NO.: C1037.70038US01

FILING DATE: December 11, 2003

CONFIRMATION NO.: 2533

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

Sheet

1

of

4

U.S. PATENT DOCUMENTS

| Examiner Initials [#] | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or Issue of Cited Document MM-DD-YYYY |
|-----------------------------------|-------------|----------------------|--------------|--|---|
| | | Number | Kind Code | | |
| | A301 | 5,416,203 | | Letsinger | 05-16-1995 |
| | A302 | 5,514,788 | | Bennett et al. | 05-07-1996 |
| | A303 | 5,527,899 | | Froehler | 06-18-1996 |
| | A304 | 5,587,361 | | Cook et al. | 12-24-1996 |
| | A305 | 5,877,309 | | McKay et al. | 03-02-1999 |
| | A306 | 5,594,122 | | Friesen | 01-14-1997 |
| | A307 | 5,929,226 | | Padmapriya et al. | 07-27-1999 |
| | A308 | 6,030,954 | | Wu et al. | 02-29-2000 |
| | A309 | 6,221,882 | B1 | Macfarlane | 04-24-2001 |
| | A310 | 6,399,630 | B1 | Macfarlane | 06-04-2002 |
| | A311 | 6,476,000 | B1 | Agrawal et al. | 11-05-2002 |
| | A312 | 6,620,805 | B1 | Takle et al. | 09-16-2003 |
| | A313 | 6,815,429 | B2 | Agrawal | 11-09-2004 |
| | A314 | 7,049,302 | B1 | Kensil | 05-23-2006 |
| | A315 | 7,105,495 | B2 | Agrawal et al. | 09-12-2006 |
| | A316 | 7,129,222 | B2 | Van Nest et al. | 10-31-2006 |
| | A317 | 7,183,111 | B2 | Van Nest et al. | 02-27-2007 |
| | A318 | 7,223,741 | B2 | Krieg | 05-29-2007 |
| | A319 | 7,250,403 | B2 | Van Nest et al. | 07-31-2007 |
| | A320 | 7,271,156 | B2 | Krieg et al. | 07-18-2007 |
| | A321 | 2002-0168340 | A1 | Agrawal | 11-14-2002 |
| | A322 | 2003-0064945 | A1 | Akhtar et al. | 04-03-2003 |
| | A323 | 2003-0212029 | A1 | Agrawal et al. | 11-13-2003 |
| | A324 | 2006-0105979 | A1 | Agrawal et al. | 05-18-2006 |
| | A325 | 2006-0154890 | A1 | Bratzler et al. | 07-13-2006 |
| | A326 | 2006-0172966 | A1 | Lipford et al. | 08-03-2006 |
| | A327 | 2006-0188913 | A1 | Krieg et al. | 08-24-2006 |
| | A328 | 2006-0211639 | A1 | Bratzler et al. | 09-21-2006 |
| | A329 | 2006-0211644 | A1 | Krieg et al. | 09-21-2006 |
| | A330 | 2006-0217328 | A1 | Kandimalla et al. | 09-28-2006 |
| | A331 | 2006-0229271 | A1 | Krieg et al. | 10-12-2006 |
| | A332 | 2006-0241076 | A1 | Uhlmann et al. | 10-26-2006 |

EXAMINER:

/N. M. Minnifield/ (03/09/2009)

DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|---|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/735,592 | ATTY. DOCKET NO.: C1037.70038US01 |
| | | | | FILING DATE: December 11, 2003 | CONFIRMATION NO.: 2533 |
| | | | | APPLICANT: Krieg et al. | |
| | | | | GROUP ART UNIT: 1645 | EXAMINER: Nita M. Minnifield |
| Sheet | 2 | of | 4 | | |

| | | | | | |
|--|------|--------------|----|------------------|------------|
| | A333 | 2006-0246035 | A1 | Ahluwalia et al. | 11-02-2006 |
| | A334 | 2006-0286070 | A1 | Hartmann et al. | 12-21-2006 |
| | A335 | 2006-0287263 | A1 | Davis et al. | 12-21-2006 |
| | A336 | 2007-0009482 | A1 | Krieg et al. | 01-11-2007 |
| | A337 | 2007-0010470 | A1 | Krieg et al. | 01-11-2007 |
| | A338 | 2007-0037767 | A1 | Bratzler et al. | 02-15-2007 |
| | A339 | 2007-0065467 | A1 | Krieg et al. | 03-22-2007 |
| | A340 | 2007-0066553 | A1 | Krieg et al. | 03-22-2007 |
| | A341 | 2007-0066554 | A1 | Krieg et al. | 03-22-2007 |
| | A342 | 2007-0078104 | A1 | Krieg et al. | 04-05-2007 |
| | A343 | 2007-0129320 | A9 | Davis et al. | 06-07-2007 |
| | A344 | 2007-0142315 | A1 | Forsbach et al. | 06-21-2007 |
| | A345 | 2007-0184465 | A1 | Wagner et al. | 08-09-2007 |
| | A346 | 2007-0202128 | A1 | Krieg et al. | 08-30-2007 |
| | A347 | 2007-0224210 | A1 | Krieg et al. | 09-27-2007 |
| | A348 | 2007-0232622 | A1 | Lipford et al. | 10-04-2007 |
| | A349 | 2008-0009455 | A9 | Krieg et al. | 01-10-2008 |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials # | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|--------------------------|-------------|-------------------------|-------------|--------------|---|---|----------------------|
| | | Office/ Country | Number | Kind Code | | | |
| | B90 | WO | 95/03407 | | Gen-Probe Incorporated | 02-02-1995 | |
| | B91 | WO | 99/63975 | A2 | Biognostik Gesellschaft Fur Biomolekular Diagnostik MBH | 12-16-1999 | |
| | B92 | WO | 00/14217 | A2 | CPG Immunopharmaceuticals GMBH | 03-16-2000 | |
| | B93 | WO | 00/67023 | A1 | CPG Immunopharmaceuticals GMBH | 11-09-2000 | |
| | B94 | WO | 02/036767 | A3 | INEX Pharmaceuticals Corporation | 05-10-2002 | |
| | B95 | WO | 2006/080946 | A2 | Coley Pharmaceutical GMBH | 08-03-2006 | |
| | B96 | WO | 2007/031877 | A2 | Coley Pharmaceutical GMBH | 03-22-2007 | |
| | B97 | WO | 2007/038720 | A2 | Coley Pharmaceutical GMBH | 04-05-2007 | |

OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials # | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|--------------------------|------------|---|----------------------|
| | C314 | Press Release, January 2007, "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy". | |

| | |
|--|------------------|
| EXAMINER: /N. M. Minnifield/ (03/09/2009) | DATE CONSIDERED: |
|--|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|---|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/735,592 | ATTY. DOCKET NO.: C1037.70038US01 |
| | | | | FILING DATE: December 11, 2003 | CONFIRMATION NO.: 2533 |
| | | | | APPLICANT: Krieg et al. | |
| | | | | GROUP ART UNIT: 1645 | EXAMINER: Nita M. Minnifield |
| Sheet | 3 | of | 4 | | |

| | |
|------|--|
| C315 | Press Release, June 2007, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer". |
| C316 | BENNETT, Intracellular delivery of oligonucleotides with cationic liposomes. In: Delivery Strategies for Antisense Oligonucleotide Therapeutics. Akthar, Ed. 1995:223-32. |
| C317 | BHAGAT et al., CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun. 2003 Jan 24;300(4):853-61. |
| C318 | CHO et al., Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a t-helper cell-independent mechanism. Nature. 2000 May; 18:509-14. |
| C319 | DAVIS et al., DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Mt Sinai J Med. 1999 Mar;66(2):84-90. Review. |
| C320 | HORNER et al., Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant. Clin Immunol. 2000 Apr;95(1 Pt 2):S19-29. |
| C321 | KLINMAN et al., CpG DNA: recognition by and activation of monocytes. Microbes Infect. 2002 Jul;4(9):897-901. |
| C322 | KRIEG, Now I know my CpGs. Trends Microbiol. 2001 Jun;9(6):249-52. |
| C323 | LEE et al., Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials. J Immunol. 2000 Oct 1;165(7):3631-9. |
| C324 | LI et al., Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine. 2001 Oct 12;20(1-2):148-57. |
| C325 | LIPFORD et al., Poly-guanosine motifs costimulate antigen-reactive CD8 T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines. Immunology. 2000 Sep;101(1):46-52. |
| C326 | MAURER et al., CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol. 2002 Aug;32(8):2356-64. |
| C327 | NORMAN et al., Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation. Gene Ther. 2000;7:1425-30. |
| C328 | OEHEN et al., Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA. Immunology. 2000 Feb;99(2):163-9. |
| C329 | OXENIUS et al., CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol. 1999 May;73(5):4120-6. |
| C330 | SHIROTA et al., Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol. 2001 Jul 1;167(1):66-74. |
| C331 | TOKUNAGA, Response of the organism to DNA - With a focus on immunostimulatory DNA. Kansenshoshu Meneki. 2001 Autumn; 31(3): 1-12. Japanese. |
| C332 | UHLMANN et al., Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel. 2003 Mar;6(2):204-17. |
| C333 | VON HUNOLSTEIN et al., The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine. 2001 Apr 30;19(23-24):3058-66. |
| C334 | WHALEN et al., DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Ann N Y Acad Sci. 1995 Nov 27;772:64-76. |

| | |
|--|------------------|
| EXAMINER: /N. M. Minnifield/ (03/09/2009) | DATE CONSIDERED: |
|--|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|---|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/735,592 | ATTY. DOCKET NO.: C1037.70038US01 |
| | | | | FILING DATE: December 11, 2003 | CONFIRMATION NO.: 2533 |
| | | | | APPLICANT: Krieg et al. | |
| | | | | GROUP ART UNIT: 1645 | EXAMINER: Nita M. Minnifield |
| Sheet | 4 | of | 4 | | |

| | | | |
|--|------|---|--|
| | C335 | WHITMORE et al., Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. <i>Canc Immun Immunother.</i> 2001;50:503-14. | |
| | C336 | YU et al., 'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. <i>Nucleic Acids Res.</i> 2002 Oct 15;30(20):4460-9. | |
| | C337 | YU et al., Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. <i>Bioorg Med Chem Lett.</i> 2001 Sep 3;11(17):2263-7. | |
| | C338 | ZHANG et al., Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. <i>Antimicrob Agents Chemother.</i> 1999 Feb;43(2):347-53. | |
| | C339 | ZHAO et al., Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. <i>Bioorg Med Chem Lett.</i> 2000 May 15;10(10):1051-4. Abstract Only. | |

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

| | |
|--|------------------|
| EXAMINER: /N. M. Minnifield/ (03/09/2009) | DATE CONSIDERED: |
|--|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.